---
title: "Halozyme director Bernadette Connaughton sells 1,625 shares worth $124,370.63"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291587684.md"
description: "Halozyme Therapeutics director Bernadette Connaughton sold 1,625 common shares on July 1, 2026, at weighted average prices between $76.40 and $77.21, totaling approximately $124,370. Following the transaction, her direct holdings decreased to 42,044 shares."
datetime: "2026-07-02T20:43:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291587684.md)
  - [en](https://longbridge.com/en/news/291587684.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291587684.md)
generator: "portal-rs"
---

# Halozyme director Bernadette Connaughton sells 1,625 shares worth $124,370.63

-   Halozyme director Bernadette Connaughton sold 1,625 common shares on July 1, 2026 at weighted average prices of $76.4 and $77.21. \* Her direct holdings fell to 42,044 shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000094), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [HALO.US](https://longbridge.com/en/quote/HALO.US.md)

## Related News & Research

- [Halozyme CEO Helen Torley sells USD 4.13 million in common shares](https://longbridge.com/en/news/296412342.md)
- [Halozyme director Bernadette Connaughton disposes of 1.626 shares worth $167.152,8](https://longbridge.com/en/news/295584667.md)
- [Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/296450253.md)
- [Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $167,152.80 in Stock](https://longbridge.com/en/news/295589663.md)
- [Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged](https://longbridge.com/en/news/296135927.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**